Floatz logo

Prior Mb-106 Car-T Cell Investigational Product.

Waldenstrom's Macroglobulinemia Recurrent

Mustang BioCell therapyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

59 Active assets in the Waldenstrom's Macroglobulinemia Recurrent cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Fred Hutchinson Cancer Center
Phase 2BBB
Cyclophosphamide
Institute of Hematology & Blood Diseases Hospital, China
Phase 2BBB
Fludarabine
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
Inno-206
BeOne Medicines
Phase 2BBB
PREDNISONE TABLETS
BeOne Medicines
Phase 2BBB

View all 50 →

Same molecule, other indications

Prior Mb-106 Car-T Cell Investigational Product. is also rated in:

B-cell chronic lymphocytic leukemiaDormant
D
Indicative ·
30 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
D
Indicative ·
30 / 100
View asset →
CD4+/CD56+ hematodermic neoplasmDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →